The current price-to-earnings ratio for Gyre Therapeutics stock as of May 8, 2025 is 67.71. This is calculated based on the current EPS of $0.14 and the stock price of $9.48 per share.
The average historical PE ratio of Gyre Therapeutics for the last nine years is 58.55. The current PE ratio of 67.71 is 16% above the historical average. In the past nine years, GYRE's PE ratio was at its highest in the Dec 2022 quarter at 197.8, when the stock price was $7.91 and the EPS was $0.04. The lowest value was in the Mar 2023 quarter, when it reached 0.44 with a price of $3.11 and an EPS of $6.98.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 86.43 | N/A | $12.1 | $0.14 |
2023 | N/A | N/A | $25.69 | -$1.41 |
2022 | 197.8 | N/A | $7.91 | $0.04 |
2021 | N/A | N/A | $13.71 | -$43.05 |
2020 | N/A | N/A | $94.65 | -$43.95 |
2019 | N/A | N/A | $102.15 | -$69 |
2018 | N/A | N/A | $118.35 | -$40.2 |
2017 | N/A | N/A | $204.6 | -$111.75 |
2016 | N/A | N/A | $146.25 | -$326.25 |
2015 | N/A | N/A | $704.25 | -$749.85 |
2014 | N/A | N/A | $4,142.25 | -$4,047.75 |
2013 | N/A | N/A | $6,536.25 | -$6,140.25 |
2012 | N/A | N/A | $6,898.5 | -$330.75 |
2011 | N/A | N/A | $8,772.75 | -$425.25 |
2010 | 69.74 | N/A | $41,737.5 | $598.5 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 86.43 | N/A | $12.1 | $0.14 |
Sep 2024 | N/A | N/A | $12.54 | -$1.4 |
Jun 2024 | N/A | N/A | $11.93 | -$1.35 |
Mar 2024 | N/A | N/A | $17.48 | -$1.36 |
Dec 2023 | N/A | N/A | $25.69 | -$1.41 |
Sep 2023 | N/A | N/A | $7.23 | -$15.13 |
Jun 2023 | N/A | N/A | $5.27 | -$17.59 |
Mar 2023 | 0.44 | -99.78% | $3.11 | $6.98 |
Dec 2022 | 197.8 | 14,772.18% | $7.91 | $0.04 |
Sep 2022 | 1.33 | N/A | $7.56 | $5.7 |
Jun 2022 | N/A | N/A | $26.7 | -$3.9 |
Mar 2022 | N/A | N/A | $9.9 | -$38.1 |
Dec 2021 | N/A | N/A | $13.71 | -$43.05 |
Sep 2021 | N/A | N/A | $61.65 | -$46.65 |
Jun 2021 | N/A | N/A | $64.95 | -$45.6 |
The current PE ratio of GYRE is above the 10-year historical average.
Stock name | PE ratio | Market cap |
---|---|---|
GYRE Gyre Therapeutics Inc | 67.71 | $887.45M |
OLMA Olema Pharmaceuticals Inc | N/A | $319.12M |
OMER Omeros Corp | N/A | $366.38M |
VIVS VivoSim Labs Inc. | N/A | $2.88M |
ORIC Oric Pharmaceuticals Inc | N/A | $378.19M |
ORMP Oramed Pharmaceuticals Inc | N/A | $93.55M |
The price to earnings ratio for GYRE stock is 67.71 as of May 8, 2025.
Over the last nine years, the quarterly PE ratio reached a historic high of 197.8 in the Dec 2022 quarter.
The current price to earnings ratio of GYRE is 16% higher than the 9-year historical average.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (May 8, 2025), Gyre Therapeutics's stock price is $9.48. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $0.14. Therefore, Gyre Therapeutics's P/E ratio for today is 67.71. PE RATIO(67.71) = STOCK PRICE($9.48) / TTM EPS($0.14)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.